Sangamo Therapeutics receives Nasdaq delisting notice; trading to be suspended May 5, 2026

SANGAMO THERAPEUTICS, INC

Nasdaq staff determined to delist SGMO due to failure to meet minimum bid price requirement.
Trading will be suspended at open on May 5, 2026; company plans to appeal before Nasdaq Hearings Panel.
Common stock approved for quotation on OTCQB Venture Market starting May 5, 2026 under symbol SGMO.
Company previously received two compliance periods but remained non-compliant with bid price rule.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.